HilleVax Inc. (HLVX)
1.75
-0.04 (-2.23%)
At close: Mar 03, 2025, 3:59 PM
1.75
0.00%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.74 |
| Market Cap | 87.16M |
| Revenue (ttm) | 2.89M |
| Net Income (ttm) | -151.57M |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -0.57 |
| Forward PE | -1.07 |
| Analyst | Hold |
| Ask | 1.85 |
| Volume | 175,136 |
| Avg. Volume (20D) | 257,084 |
| Open | 1.79 |
| Previous Close | 1.79 |
| Day's Range | 1.75 - 1.81 |
| 52-Week Range | 1.55 - 20.22 |
| Beta | 0.73 |
About HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts....
Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 90
Stock Exchange NASDAQ
Ticker Symbol HLVX
Website https://www.hillevax.com
Analyst Forecast
According to 5 analyst ratings, the average rating for HLVX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 14.29% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
2 months ago
+7.49%
HilleVax shares are trading higher. The stock may ...
Unlock content with
Pro Subscription
7 months ago
-88.34%
HilleVax shares are trading lower after the company announced the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants.
